What is calquence? Understanding this targeted cancer therapy
•
3 min read
First approved by the FDA in 2017 for mantle cell lymphoma, **calquence** (acalabrutinib) is a targeted oral medication used to treat certain B-cell malignancies. It is not a traditional chemotherapy drug but a Bruton's tyrosine kinase (BTK) inhibitor, a class of targeted therapies that work by interrupting specific signaling pathways within cancer cells. This targeted approach aims to limit the negative effects on healthy cells, offering a more precise treatment method.
